News & Events

Efficacy and safety of immune checkpoint inhibitor plus bevacizumab-based chemotherapy in advanced or recurrent KRAS-mutant non-squamous NSCLC: the SPIRAL-STONE study

Efficacy and safety of immune checkpoint inhibitor plus bevacizumab-based chemotherapy in advanced or recurrent KRAS-mutant non-squamous NSCLC: the SPIRAL-STONE study

Trethera wins Fast Track for dCK inhibitor TRE-515 in KRAS G12C lung cancer combination

Trethera wins Fast Track for dCK inhibitor TRE-515 in KRAS G12C lung cancer combination

FDA Grants Fast Track Designation to TRE-515 for KRAS G12C NSCLC

FDA Grants Fast Track Designation to TRE-515 for KRAS G12C NSCLC

FDA Grants Fast Track Designation to TRE-515 Plus KRAS Inhibitors in Pretreated KRAS G12C+ NSCLC

FDA Grants Fast Track Designation to TRE-515 Plus KRAS Inhibitors in Pretreated KRAS G12C+ NSCLC

KST-6051 Receives FDA Fast Track Designation in KRAS-Mutant Solid Tumors

KST-6051 Receives FDA Fast Track Designation in KRAS-Mutant Solid Tumors

Inside Setidegrasib’s Phase 3 Development: Targeting KRAS G12D Through Protein Degradation

Inside Setidegrasib’s Phase 3 Development: Targeting KRAS G12D Through Protein Degradation

Why KRAS G12C May Drive a Survival Benefit With Cemiplimab in NSCLC

Why KRAS G12C May Drive a Survival Benefit With Cemiplimab in NSCLC